A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Histamine dihydrochloride (Primary) ; Aldesleukin
- Indications Cancer metastases; Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Maxim Pharmaceuticals
- 25 Sep 2005 New trial record.